Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: Potential for breast cancer therapy

Roza K. Sypniewska, Lieve Hoflack, Melissa Tarango, Susan Gauntt, Belinda Z. Leal, Robert L. Reddick, Claudia Gravekamp

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Anti-tumor vaccines are a relatively non-toxic alternative to conventional chemotherapeutic strategies to control breast cancer. Immunization with tumor-associated antigens (TAAs) triggers anti-tumor cytotoxic T lymphocytes (CTL), which can limit tumor progression. Here we report on the development and effectiveness of a TAA-based DNA vaccine encoding Mage-b1/2, the mouse homologue of the human MAGE-B1/2. As model system, we used immune competent Balb/c mice with syngeneic non-metastatic (64pT) or metastatic (4TO7cg) breast tumors. First, the presence of Mage-btranscripts in the 64pT and 4TO7cg breast tumors and metastases was demonstrated by RT-PCR, Southern blotting, and DNA sequencing. A DNA-based vaccine was developed from transcripts of one of the 64pT tumors, encoding the complete Mage-b1/2 protein, and subsequently tested for its preventive efficacy in both breast tumor models. Mice were immunized two times intramuscularly with the vaccine (pcDNA3.1-Mage-b1/2-V5), the control vector (pcDNA3.1-V5), or saline. Two weeks after the last immunization, the syngeneic 4TO7cg or 64pT tumor cell lines were injected in a mammary fat pad. Mice were monitored during the next 4 weeks for tumor formation, latency and size, and subsequently sacrificed for analysis. While the Mage-b1/2 vaccine had only a minor effect on the latency and growth of primary tumors, a significant and reproducible reduction in the number of 4TO7cg metastases was observed (vaccine versus control vector, p=0.0329; vaccine versus saline, p=0.0128). The observed protective efficacy of the Mage-b DNA vaccine correlated with high levels of vaccine-induced IFNγ in spleen and lymph nodes upon re-stimulation in vitro. These results demonstrate the potential of TAA-based DNA vaccines in controlling metastatic disease in breast cancer patients.

Original languageEnglish (US)
Pages (from-to)19-28
Number of pages10
JournalBreast Cancer Research and Treatment
Volume91
Issue number1
DOIs
StatePublished - May 2005
Externally publishedYes

Fingerprint

DNA Vaccines
Vaccines
Breast Neoplasms
Neoplasm Metastasis
Neoplasm Antigens
Neoplasms
Immunization
Therapeutics
Cancer Vaccines
Cytotoxic T-Lymphocytes
Southern Blotting
Tumor Cell Line
DNA Sequence Analysis
Adipose Tissue
Immune System
Breast
Spleen
Lymph Nodes
Polymerase Chain Reaction
Growth

Keywords

  • 4TO7cg model
  • 64pT model
  • Breast tumor model
  • Mage-b DNA vaccine
  • Metastases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model : Potential for breast cancer therapy. / Sypniewska, Roza K.; Hoflack, Lieve; Tarango, Melissa; Gauntt, Susan; Leal, Belinda Z.; Reddick, Robert L.; Gravekamp, Claudia.

In: Breast Cancer Research and Treatment, Vol. 91, No. 1, 05.2005, p. 19-28.

Research output: Contribution to journalArticle

Sypniewska, Roza K. ; Hoflack, Lieve ; Tarango, Melissa ; Gauntt, Susan ; Leal, Belinda Z. ; Reddick, Robert L. ; Gravekamp, Claudia. / Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model : Potential for breast cancer therapy. In: Breast Cancer Research and Treatment. 2005 ; Vol. 91, No. 1. pp. 19-28.
@article{314fbfe93697415b827b16ce9d8e4c38,
title = "Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: Potential for breast cancer therapy",
abstract = "Anti-tumor vaccines are a relatively non-toxic alternative to conventional chemotherapeutic strategies to control breast cancer. Immunization with tumor-associated antigens (TAAs) triggers anti-tumor cytotoxic T lymphocytes (CTL), which can limit tumor progression. Here we report on the development and effectiveness of a TAA-based DNA vaccine encoding Mage-b1/2, the mouse homologue of the human MAGE-B1/2. As model system, we used immune competent Balb/c mice with syngeneic non-metastatic (64pT) or metastatic (4TO7cg) breast tumors. First, the presence of Mage-btranscripts in the 64pT and 4TO7cg breast tumors and metastases was demonstrated by RT-PCR, Southern blotting, and DNA sequencing. A DNA-based vaccine was developed from transcripts of one of the 64pT tumors, encoding the complete Mage-b1/2 protein, and subsequently tested for its preventive efficacy in both breast tumor models. Mice were immunized two times intramuscularly with the vaccine (pcDNA3.1-Mage-b1/2-V5), the control vector (pcDNA3.1-V5), or saline. Two weeks after the last immunization, the syngeneic 4TO7cg or 64pT tumor cell lines were injected in a mammary fat pad. Mice were monitored during the next 4 weeks for tumor formation, latency and size, and subsequently sacrificed for analysis. While the Mage-b1/2 vaccine had only a minor effect on the latency and growth of primary tumors, a significant and reproducible reduction in the number of 4TO7cg metastases was observed (vaccine versus control vector, p=0.0329; vaccine versus saline, p=0.0128). The observed protective efficacy of the Mage-b DNA vaccine correlated with high levels of vaccine-induced IFNγ in spleen and lymph nodes upon re-stimulation in vitro. These results demonstrate the potential of TAA-based DNA vaccines in controlling metastatic disease in breast cancer patients.",
keywords = "4TO7cg model, 64pT model, Breast tumor model, Mage-b DNA vaccine, Metastases",
author = "Sypniewska, {Roza K.} and Lieve Hoflack and Melissa Tarango and Susan Gauntt and Leal, {Belinda Z.} and Reddick, {Robert L.} and Claudia Gravekamp",
year = "2005",
month = "5",
doi = "10.1007/s10549-004-6454-7",
language = "English (US)",
volume = "91",
pages = "19--28",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model

T2 - Potential for breast cancer therapy

AU - Sypniewska, Roza K.

AU - Hoflack, Lieve

AU - Tarango, Melissa

AU - Gauntt, Susan

AU - Leal, Belinda Z.

AU - Reddick, Robert L.

AU - Gravekamp, Claudia

PY - 2005/5

Y1 - 2005/5

N2 - Anti-tumor vaccines are a relatively non-toxic alternative to conventional chemotherapeutic strategies to control breast cancer. Immunization with tumor-associated antigens (TAAs) triggers anti-tumor cytotoxic T lymphocytes (CTL), which can limit tumor progression. Here we report on the development and effectiveness of a TAA-based DNA vaccine encoding Mage-b1/2, the mouse homologue of the human MAGE-B1/2. As model system, we used immune competent Balb/c mice with syngeneic non-metastatic (64pT) or metastatic (4TO7cg) breast tumors. First, the presence of Mage-btranscripts in the 64pT and 4TO7cg breast tumors and metastases was demonstrated by RT-PCR, Southern blotting, and DNA sequencing. A DNA-based vaccine was developed from transcripts of one of the 64pT tumors, encoding the complete Mage-b1/2 protein, and subsequently tested for its preventive efficacy in both breast tumor models. Mice were immunized two times intramuscularly with the vaccine (pcDNA3.1-Mage-b1/2-V5), the control vector (pcDNA3.1-V5), or saline. Two weeks after the last immunization, the syngeneic 4TO7cg or 64pT tumor cell lines were injected in a mammary fat pad. Mice were monitored during the next 4 weeks for tumor formation, latency and size, and subsequently sacrificed for analysis. While the Mage-b1/2 vaccine had only a minor effect on the latency and growth of primary tumors, a significant and reproducible reduction in the number of 4TO7cg metastases was observed (vaccine versus control vector, p=0.0329; vaccine versus saline, p=0.0128). The observed protective efficacy of the Mage-b DNA vaccine correlated with high levels of vaccine-induced IFNγ in spleen and lymph nodes upon re-stimulation in vitro. These results demonstrate the potential of TAA-based DNA vaccines in controlling metastatic disease in breast cancer patients.

AB - Anti-tumor vaccines are a relatively non-toxic alternative to conventional chemotherapeutic strategies to control breast cancer. Immunization with tumor-associated antigens (TAAs) triggers anti-tumor cytotoxic T lymphocytes (CTL), which can limit tumor progression. Here we report on the development and effectiveness of a TAA-based DNA vaccine encoding Mage-b1/2, the mouse homologue of the human MAGE-B1/2. As model system, we used immune competent Balb/c mice with syngeneic non-metastatic (64pT) or metastatic (4TO7cg) breast tumors. First, the presence of Mage-btranscripts in the 64pT and 4TO7cg breast tumors and metastases was demonstrated by RT-PCR, Southern blotting, and DNA sequencing. A DNA-based vaccine was developed from transcripts of one of the 64pT tumors, encoding the complete Mage-b1/2 protein, and subsequently tested for its preventive efficacy in both breast tumor models. Mice were immunized two times intramuscularly with the vaccine (pcDNA3.1-Mage-b1/2-V5), the control vector (pcDNA3.1-V5), or saline. Two weeks after the last immunization, the syngeneic 4TO7cg or 64pT tumor cell lines were injected in a mammary fat pad. Mice were monitored during the next 4 weeks for tumor formation, latency and size, and subsequently sacrificed for analysis. While the Mage-b1/2 vaccine had only a minor effect on the latency and growth of primary tumors, a significant and reproducible reduction in the number of 4TO7cg metastases was observed (vaccine versus control vector, p=0.0329; vaccine versus saline, p=0.0128). The observed protective efficacy of the Mage-b DNA vaccine correlated with high levels of vaccine-induced IFNγ in spleen and lymph nodes upon re-stimulation in vitro. These results demonstrate the potential of TAA-based DNA vaccines in controlling metastatic disease in breast cancer patients.

KW - 4TO7cg model

KW - 64pT model

KW - Breast tumor model

KW - Mage-b DNA vaccine

KW - Metastases

UR - http://www.scopus.com/inward/record.url?scp=18844372588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18844372588&partnerID=8YFLogxK

U2 - 10.1007/s10549-004-6454-7

DO - 10.1007/s10549-004-6454-7

M3 - Article

C2 - 15868428

AN - SCOPUS:18844372588

VL - 91

SP - 19

EP - 28

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -